Search

Displaying results 3821 - 3830 of 7284 in total
  1. Drug

    Viper antivenom

    go.drugbank.com/drugs/DB14114
    ApprovedInvestigational

    ANAVIP, an equine-derived antivenom made with venom from _Bothrops asper_ and _Crotalus durissus_, was first approved by the FDA on October 1, 2015, for the management of North American rattlesnake envenomation

  2. Drug

    Asapiprant

    go.drugbank.com/drugs/DB20492
    Investigational

    Asapiprant has a monoisotopic molecular weight of 501.16 Da. … Asapiprant is a small molecule drug.

  3. Drug

    Alofanib

    go.drugbank.com/drugs/DB20918
    Investigational

    Alofanib has a monoisotopic molecular weight of 413.07 Da. … Alofanib is a small molecule drug. The usage of the INN stem '-anib' in the name indicates that Alofanib is a angiogenesis inhibitor.

  4. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    Tradipitant is a selective, high-affinity antagonist at human substance P/neurokinin-1 (NK-1) receptors. … [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion.

  5. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Food and Drug Administration (FDA) on June 17, 2005. … Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil.

    Products: TIGECLIN ® POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE., TIGEVITAE® 50 MG POLVO LIOFILIZADO PARA RECONSTITUIR A SOLUCION INYECTABLE
  6. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  7. Drug

    Dexfenfluramine

    go.drugbank.com/drugs/DB01191
    ApprovedIllicitWithdrawn

    For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. … Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug.

    Synonyms: d-N-ethyl-α-methyl-m-trifluoromethylphenethylamine
  8. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    [A31581] Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018.[L48621] … Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus.

  9. Drug

    Carfilzomib

    go.drugbank.com/drugs/DB08889
    ApprovedInvestigational

    Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. … FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.[L39392]

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index
  10. Drug

    Pegfilgrastim

    go.drugbank.com/drugs/DB00019
    ApprovedInvestigational

    There are several pegfilgrastim biosimilars (Fulphila, Pelgraz or Lapelga, Pelmeg, Udenyca, Ziextenzo, Grasustek, Fylnetra, Stimufend) by Health Canada, European Union (EU), and FDA that are approved to … [A187607] First developed by Amgen, pegfilgrastim was initially approved by the FDA in 2002 and marketed as Neulasta. It is typically administered via a subcutaneous injection.

    Categories: Compounds used in a research, industrial, or household setting, Complex MixturesProducts: Pelgraz 6 mg solution for injection in a pre-filled syringe, NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML